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Abstract 
AIM: Aim of the study was to compare outcomes of pregnancy in gestational diabetes mellitus (GDM) treated with 
metformin, insulin, or diet. 
MATERIAL AND METHODS: The study included 48 women with GDM treated with metformin, 101 with insulin, 
and 200 women on a diet from the Outpatient Department of Endocrinology and University Clinic of Obstetrics 
and Gynecology in Skopje. 
RESULTS: The groups were comparable in age, smoking cigarettes and positive family history of diabetes. Mean 
glycosylated haemoglobin (HbA1c) at 37 gestation week, mean fasting, postprandial glycaemia, and gestational 
age at delivery were lower in diet and metformin than insulin group. No differences in mode of delivery were 
observed between the metformin and insulin group. Women in metformin group had a significantly lower 
incidence of LGA newborns than diet and insulin groups. The percent of SGA new-borns was higher in insulin 
group than diet and metformin groups. The incidence of neonatal hypoglycemia was statistically significantly 
higher in the insulin group than in the metformin and diet group. 
CONCLUSION: Metformin in women with GDM can improve maternal and neonatal outcomes compared with 
those treated with diet or insulin. 
 
 
 
 
 
 
 
Introduction 
 
Pregnancy itself is characterised by insulin 
resistance [1]. Gestational diabetes mellitus (GDM) 
develops if there is inadequate insulin secretion to 
compensate insulin resistance.  
GDM increases the risk of pregnancy 
complications and adverse neonatal outcomes. 
Excessive mother to fetus glucose transfer increases 
the risk for large or small for gestational age newborn, 
neonatal hypoglycaemia and neonatal respiratory 
distress syndrome, as well as increased risk for 
preeclampsia, cesarean, preterm delivery and higher 
risk for development of type 2 diabetes mellitus after 
pregnancy in women with GDM. Meta-analysis of 
several randomised trials has shown that appropriate 
therapy can decrease maternal and fetal morbidity [2] 
[3]. An effective treatment regimen consists of diet 
alone for most patients and the administration of 
insulin if target blood glucose concentrations are not 
met with diet alone.  
Prospective randomised studies 
demonstrated that effective treatment of 
hyperglycemia in women with GDM could reduce 
adverse perinatal outcomes [2]. The treatment is with 
diet, metformin or insulin. Insulin treatment is safe and 
effective for pregnant women, but the disadvantages 
of insulin are: need to give injections, the risk of 
hypoglycemia, the risk of excessive weight gain, and 
cost [1]. Therefore, oral metformin is a logical option 
for pregnant women with GDM. It does not induce 
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hypoglycemia, and it is not associated with increased 
weight gain. Also, metformin improves insulin 
sensitivity probably by activating AMP kinase and 
reduces hepatic gluconeogenesis, which could be 
beneficial for preservation of β–cell function [1]. But it 
has been found that metformin has a maternal to the 
fetal transfer rate of 10-16% which might be 
associated with fetal anomalies or potential adverse 
effects for mother and newborns [4].  
The randomised trials and observational 
studies observed that maternal glucose levels did not 
differ between pregnant women treated with insulin 
versus those treated with an oral glucose-lowering 
agent such as metformin. There is a small number of 
studies reporting on the use of metformin during GDM 
pregnancy. They provide conflicting information about 
the safety of metformin use in GDM pregnancies or 
type 2 diabetes and pregnancy [1] [10] [17].  
The study aimed to compare maternal and 
neonatal outcomes in patients with gestational 
diabetes mellitus (GDM) treated with metformin 
versus those with insulin, or diet alone. 
 
 
Material and Methods 
 
Three hundred and forty-nine women with 
GDM that have consulted the Outpatient Department 
of University Clinic of Endocrinology Diabetes and 
Metabolic Disorders were enrolled. From them, 48 
women were treated with metformin, 101 with insulin, 
and 200 received no pharmacological treatment, were 
treated only with the dietary regimen. All were with 
singleton pregnancies and gave informed consent to 
participate in the study. 
The diagnosis for GDM was made with 75 gr 
OGTT (normal values: a fasting level < 5.1; 1-hour 
level < 10.0 and 2-hour level < 8.5 mmol/L), according 
to The International Association for Diabetes and 
Pregnancy Study Group (IADPSG). Only one 
abnormal plasma glucose level was sufficient for the 
diagnosis of GDM4  
The studied outcome measures were: 
glycemic control, maternal, and neonatal outcomes.  
All women were asked to perform a daily 
glucose profile (fasting, pre-prandial and 1-h 
postprandial measurements) twice a week from the 
diagnostic moment of GDM until delivery, using a 
home glucometer (OneTouch Basic 200-200; 
LifeScan, Milpitas, California, USA). Multiple daily 
measurements (at least four a day) allowed 
recognition of women who should begin an anti-
hyperglycemic agent. The desirable target glucose 
levels were: fasting glycaemia between 3.8 to 5.0 
mmol/l and one-hour postprandial blood glucose 
concentration < 7.8 mmol/l (American Diabetes 
Association). At 37 week of gestation after overnight 
fasting, HbA1c was taken and was measured by 
anion-exchange HPLC instrument (DS5; Drew, USA) 
with a reference range of 4.2–6.5%. 
The mode of treatment (diet, metformin or 
insulin), based on self-monitored plasma glucose 
values, was determined within a week after starting 
monitoring. Women with GDM on a diet were 
educated regarding an individualised diabetic diet 
based on pre-pregnancy weight (30 kcal/kg/day) with 
a caloric restriction for overweight and obese women 
(25 kcal/kg/day). Metformin was given at a dose of 
500 mg three times a day to a maximum of 2000 
mg/day based on the glycemic profile. Adjustments in 
the insulin doses were made if two or more glycaemic 
values were consistently higher than the target blood 
glucose concentrations, in a two-week interval. Insulin 
therapy in the regime of multiple injections of short 
(apart) and long-lasting analogue (detemir) was 
introduced, starting from 0.3 IU/kg of body weight. 
According to blood glucose profile, the insulin doses 
were changed by 2 to 4 units at a time.  
At the first visit all patients were asked about 
their age, weight before pregnancy, gestational week, 
smoking habits and familial history of diabetes. Body 
mass index before pregnancy was calculated 
retrospectively. Weight before delivery was measured 
again in all patients wearing clothes without shoes in 
the morning. Height was measured to the nearest 1 
cm with a stadiometer.  
At every visit, blood pressure was measured 
twice in a supine position. In a case of hypertension 
(>145/90 mmHg), the measurement was repeated 
after five minutes. Preeclampsia was registered if 
blood pressure was >140/90 mmHg with proteinuria 
>0.3 g/24 h.  
Mode of delivery was noted as spontaneous, 
assisted or caesarean section. Birth weight and the 
proportion of LGA (defined as birth weight > 90th 
percentile for local population after adjusting for 
gestational age and sex) and SGA (defined as a birth 
weight < 10th percentile for local population after 
adjusting for gestational age and sex) were 
determined. Prematurity was defined as born before 
37 gestational weeks. The gestational age of 
newborns was estimated from the date of the last 
menstrual period. Neonatal serum glycaemia was 
measured after delivery and values lower than 2.6 
mmol/l were considered as hypoglycemia. Apgar 
score was measured at 1’ and 5’ after delivery, but we 
used only values at 5’.  
All neonatal outcomes were performed in 
University Clinic of Gynecology and Obstetrics.  
Statistical analyses were performed using 
SPSS software for Windows, version 14.0. Dates are 
given as mean ± standard deviation and percent. We 
used a t-test for independent samples to compare the 
numeric variables between each of the groups; for 
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categorical variables, Chi-square test was used. 
Values of p < 0.05 were considered statistically 
significant.  
 
 
Results 
 
From 349 GDM pregnancies, 200 were 
treated with diet alone, 101 with insulin, and 48 with 
metformin.  
Baseline characteristics of the women 
enrolled in the study are given in Table 1. It can be 
seen that women treated with diet have lower BMI 
before pregnancy, but higher weight gain during 
pregnancy, then the other two groups. The weight 
gain was lowest in the metformin group. Patients 
treated with insulin enrolled earlier in the study than 
patients from other groups. Between the three groups, 
no significant differences in the incidence of smoking 
cigarettes and familial history of diabetes were noted.  
Table 1: Maternal Characteristics at Baseline 
 
Diet 
(N = 200) 
Metformin 
(N = 48) 
Insulin 
(N = 101) 
Metfom 
vs. diet 
P 
Metfom 
vs.insuli 
P 
Diet vs. 
insulin 
P 
Age (years) 31.5 ± 5.2 32.2 ± 4.7 32.7 ± 5.7 NS NS NS 
Pre- 
pregnancy 
BMI (kg/m
2
) 
26.7 ± 5.3 28.8 ± 5.3 27.5 ± 4.9 < 0.05 NS NS 
Weight gain 
(kg) 
10.9 ± 6.1 8.1 ± 4.9 8.7 ± 6.1 < 0.01 NS < 0.01 
Gestational 
week at 
enrolment 
(g.w.) 
29.5 ± 5.8 28.6 ± 5.6 24 ± 7.8 NS < 0.01 < 0.01 
Smoking 
cigarettes (%) 
20 (10%) 5 (10.4%) 11 (10.8%) NS NS NS 
Familiar 
history for 
diabetes (%) 
105 (52.5%) 24 (50%) 62 (62%) NS NS NS 
 
Mean glycosylated haemoglobin (HbA1c) at 
37 gestation week was statistically significantly lower 
in diet and metformin groups than in insulin group 
(Table 2). Mean fasting (FPG) and postprandial 
glycaemia (PPG) was statistically significantly lower in 
diet and metformin group than in insulin group (Table 
2). The percent of preeclampsia was higher in the 
metformin group but without statistical significance 
between metformin and insulin groups; only between 
diet and other two groups.  
Women treated with insulin had delivery 
earlier than those treated with metformin or diet alone. 
This difference was statistically significant. Caesarean 
deliveries were more likely in women treated with 
insulin and metformin than in the diet group (Table 2). 
The percent of LGA newborns was statistically 
significantly lower in metformin-treated group versus 
diet and insulin groups. The percent of prematurity 
was statistically significantly higher in the insulin group 
than in the diet and metformin groups. The percent of 
SGA was statistically significantly higher in the insulin 
group than in the diet and metformin groups. Mean 
birth weight in insulin group was statistically 
significantly lower than in diet and metformin groups. 
The incidence of neonatal hypoglycemia was 
statistically significantly higher in the insulin group 
compared with those treated with metformin or diet. 
There were no differences in Apgar scores in 5’ 
between the three groups (Table 3). 
Table 2: Maternal primary outcomes 
 
Diet 
(N = 200) 
Metformin 
(N = 48) 
Insulin 
(N = 101) 
Metfom 
vs. diet 
P 
Metfom 
vs.insulin 
P 
Diet vs. 
insulin 
P 
HbA1c at 37 
g.w. (mean) 
5.4 ± 0.9 5.3 ± 0.7 6.2 ± 1.8 NS < 0.01 < 0.01 
Fasting 
glycaemia 
mmol/l 
5.1 ± 0.9 5.3 ± 0.7 5.8 ± 1.4 NS <0.05 <0.01 
Postprandial 
glycaemia 
(PPG) mmol/l 
6.9 ± 1.6 7.0 ± 1.2 7.9 ± 1.9 NS <0.05 < 0.05 
Preeclampsia 1 (0.5%) 4 (8.3%) 6 (6%) < 0.01 NS < 0.01 
Gestational age 
at delivery (g.w.) 
38.9 ± 1.9 38.9 ± 1.4 37.5 ± 2.2 NS < 0.01 < 0.01 
Mode of delivery 
-spontaneous 
- assisted 
- caesarean 
section 
 
86/130 
(66.1%) 
3/130 (2.3%) 
41/130 
(31.5%) 
 
22/46(47.8
%) 
0 
24/46(52.2
%) 
 
34/100 
(34%) 
0 
66/100 
(66%) 
 
< 0.05 
NS 
< 0.05 
 
NS 
NS 
NS 
 
< 0.05 
NS 
< 0.05 
 
There were no major complications or 
perinatal deaths in this study. One neonate of a 
mother treated with insulin had asphyxia. There were 
no cases of diabetic ketoacidosis or lactic acidosis.  
Table 3: Neonatal primary outcomes 
 
Diet 
(N = 200) 
Metformin 
(N = 48) 
Insulin 
(N = 101) 
Metform 
vs. diet 
P 
Metform 
vs.insulin 
P 
Diet vs. 
insulin 
P 
Birth weight (gr) 3631 ± 650 3496 ± 480 3348 ± 739 NS NS < 0.01 
Prematurity 13 (6.5%) 2 (4.2%) 20 (19.8%) NS < 0.01 < 0.01 
LGA (> 2SD/%) 59 (29.5%) 6 (12.5%) 22 (21.7%) < 0.05 < 0.05 NS 
SGA (< 2SD/%) 8 (4%) 3 (6.2%) 14 (13.8%) NS NS < 0.01 
Neonatal 
glycaemia 
(mean, % with 
hypoglycae-
mia) 
3.3 ± 1.2 
 (24%) 
2.8 ± 1.1 
 (35.4%) 
2.6 ± 1.1 
 (51.5%) 
< 0.05 
< 0.05 
< 0.05 
< 0.05 
< 0.01 
< 0.01 
Apgar score at 
5
’
 
8.9 ± 0.7 8.6 ± 0.7 8.6 ± 0.8 NS NS NS 
LGA-large for gestational age; SGA-small for gestational age; SD-standard deviation. 
 
Correlation analysis found a statistically 
significant positive correlation between preeclampsia 
and pre-pregnancy BMI. Statistically significant 
positive correlations were found between baby birth 
weight and weight gain and between baby birth weight 
and HbA1c at 37 g.w. Also, there was statistically 
significant positive correlation between HbA1c and 
incidence of LGA newborns. Fasting plasma glucose 
values had a statistically significant positive 
correlation with pre-pregnancy BMI.  
 
 
Discussion 
Our study has shown that women with GDM 
treated with metformin had similar, even better 
outcomes than those treated with diet or insulin alone.  
Metformin reduces hyperglycemia by 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
4                                                                                                                                                                                                    https://www.id-press.eu/mjms/index 
 
suppressing hepatic glucose output (hepatic 
gluconeogenesis), increasing insulin sensitivity and 
enhancing peripheral glucose uptake [6]. The weight 
gain was lower in metformin and insulin groups 
compared to the diet group. These effects are 
potentially useful during pregnancy when glucose 
control deteriorates with changes in insulin resistance 
[7]. 
Mean HbA1c at 37 gestation week, mean 
FPG and PPG were statistically significantly lower in 
diet and metformin groups than in the insulin group. 
Better glycemic profiles in the metformin group in 
comparison to the insulin group can be explained by 
reducing insulin resistance in GDM pregnancies which 
is the main pathophysiologic way for developing 
gestational diabetes in pregnancy. Similar results 
have been noted in other studies [8]. In this study, 
HbA1c was shown as an important factor for 
increased incidence of delivery LGA newborns. The 
better glycemic control means lower risk for LGA, 
which can be achieved with metformin.  
We noted a high incidence of preeclampsia in 
the metformin group, identically as Hellmuth et al9. 
But contrary studies found that metformin may reduce 
preeclampsia in GDM women by reducing the 
endothelial activation and maternal inflammatory 
response to insulin resistance [8][10]. However, the 
percent of preeclampsia in the metformin group was 
not statistically significantly greater than the percent of 
preeclampsia in the insulin group. Fluctuating glucose 
levels have a stronger effect on endothelial function, 
which is more important in the pathogenesis of 
preeclampsia, than sustained hyperglycaemia [11] 
[12]. This can be the explanation for our findings. 
Unrelated to metformin use, other increased risk 
factors for pre-eclampsia, such as older age or 
overweight may exist. In our study, the groups were 
matched for age, but the percentage of obese woman 
in the metformin group was higher than in the insulin 
and diet groups. Also, their antihyperglycemic 
medication was started four weeks later than the 
initiation of insulin.-  
Average gestational age at delivery was 
significantly lower in the insulin group, and 
consequently, the percent of prematurity and SGA 
newborns was higher in the insulin group. Contrary 
there is a number of studies with opposite findings10, 
[13] [14] [15] [16] [17]. Only Balani et al., [14] and Goh 
et al., [18] presented identical results as ours. In their 
studies, the percent of prematurity was lower in 
women treated with metformin compared with insulin 
group. Also, they found the higher percent of 
caesarean delivery in insulin group than metformin. 
Probably, a higher percent of LGA newborns in insulin 
group was responsible for higher incidence of 
caesarean section in those patients.  
Surprisingly, although mean glycemic values 
were higher in the insulin group, the percent of SGA 
newborns was higher. It can be explained by a high 
incidence of prematurity in the insulin group. Similar 
results were presented by Lavanya et al., [19].  
We found significantly fewer macrosomic 
neonates in the metformin group than in the diet and 
insulin groups. Unlike our experience, in the MiG9 
trial, there was no significant difference in the 
proportion of LGA newborns in metformin versus 
insulin group. The addition of supplementary insulin in 
metformin group in the above study may be 
responsible. Similar results as ours were presented in 
the study of Gandhi et al., [20].  
In correlation with the previous studies [9] [17] 
[18] [21], the incidence of neonatal hypoglycemia was 
reduced in the metformin group in comparison to the 
insulin group.  
Mean Apgar scores at 5’ were almost identical 
in the metformin and insulin groups, higher than in the 
diet group, but without statistical differences. This is 
consistent with other studies [9] [21].  
The study has several limitations. It was not 
randomised, and small number women were included. 
Baseline differences between the groups might have 
influenced the outcomes.  
The percentage of GDM patients needing 
pharmacological treatment varies from 20% to 60% in 
various studies [22]. That’s not a small number. 
Insulin has several disadvantages including multiple 
daily injections, the risk of hypoglycemia and maternal 
weight gain [23]. On the other hand, metformin is 
more acceptable to women with GDM, it’s safe, with 
no significant maternal or neonatal outcomes, and has 
low cost. If metformin had any unanticipated adverse 
effect on fetal growth or well-being, there would be 
more iatrogenic preterm births [1]. But, the frequency 
of preterm births in our study was higher in the insulin 
group than in the metformin group. Metformin use in 
our study was not associated with increased perinatal 
complications. Even more, metformin treatment 
resulted in better glycemic control and improved 
neonatal outcomes compared with insulin. Because 
metformin crosses the placenta, Glueck et al., [24] 
assessed long-term effects of metformin on the 
children. They presented that growth, motor and 
social development in the offspring of mothers who 
conceived and continued on metformin did not differ 
from that of control babies over the first 18 months of 
life. So, metformin may have its place as first line 
GDM therapy, especially in a subgroup of patients that 
are overweight but not obese, but between one third 
and one half of women will need insulin to achieve 
glycemic targets. However, further clinical long-term 
follow-up studies are needed to determine the role of 
metformin as an alternative treatment to insulin in 
GDM patients. 
In conclusion, according to the current 
knowledge, metformin is effective and safe in the 
treatment of GDM, because women with GDM treated 
with metformin had less weight gain and improved 
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neonatal outcomes compared with those treated with 
diet or insulin. But it is not known whether fetal 
exposure to an insulin-sensitizing agent, such as 
metformin is beneficial or harmful, and thus caution is 
warranted in its use in pregnancy. 
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